How to Make the Final Pricing Decision in a US IPO: Balancing Issuer and Underwriter Interests

The final pricing decision in a US IPO has become the most contentious point in the deal process for Hong Kong-based issuers, particularly after the SEC’s March 2025 amendments to the accelerated filer definition and the PCAOB’s continued scrutiny of audit workpapers for China-incorporated companies. These regulatory shifts, combined with the persistent volatility in US-listed Chinese ADRs — the KraneShares CSI China Internet ETF (KWEB) recorded a 30-day realised volatility of 42% in Q1 2025 — have forced a fundamental recalibration of how issuers and underwriters negotiate price ranges. For a Hong Kong-headquartered company seeking a NYSE or NASDAQ listing, the pricing decision is no longer a simple arithmetic exercise of demand book-building; it is a strategic trade-off between maximising primary proceeds and ensuring secondary market stability, with direct implications for post-listing compliance under HKEX Listing Rules Chapter 37 (debt listings) and SFC Code of Conduct provisions on sponsor liability.

The Structural Tension Between Issuer and Underwriter Incentives

The core conflict in US IPO pricing stems from divergent risk-reward profiles. The issuer aims to maximise gross proceeds — the product of offer price and number of shares sold — while the underwriter, particularly the lead left bookrunner, seeks to minimise aftermarket price decline to protect its reputation with institutional investors and avoid inventory losses from any greenshoe over-allotment.

The Underwriter’s Pricing Calculus

Underwriters price IPOs at a discount to fair value, a phenomenon documented extensively in academic literature. For US-listed Chinese companies between 2020 and 2024, the average first-day pop was 18.7%, according to data from Dealogic and Renaissance Capital. This discount is not accidental. It serves three functions: compensating institutional investors for information asymmetry in a book-building process where due diligence is limited by time constraints; reducing the probability of a post-listing price decline below the offer price, which would damage the underwriter’s franchise; and creating a “money left on the table” buffer that incentivises buy-side clients to participate in future offerings.

The underwriter’s internal pricing model typically uses a discounted cash flow (DCF) framework cross-checked against comparable company analysis (CCA) and precedent transaction analysis (PTA). For a Hong Kong-based technology issuer with a PRC operating entity via a VIE structure, the underwriter applies a 15-25% holding company discount to account for regulatory uncertainty — a practice the SEC’s Division of Corporation Finance has flagged in comment letters since the Holding Foreign Companies Accountable Act (HFCAA) took effect in 2021.

The Issuer’s Pricing Objectives

The issuer’s CFO and board of directors, advised by the Hong Kong-based sponsor (保薦人), evaluate pricing against three benchmarks: the pre-IPO valuation from the latest funding round, the valuation of comparable US-listed peers, and the internal rate of return (IRR) required by existing venture capital or private equity shareholders. For a Cayman Islands-incorporated, PRC-operating company, the board must also consider the impact of pricing on the conversion price of any outstanding convertible notes or preference shares held by strategic investors.

The tension crystallises during the pricing call, which typically occurs after the NYSE or NASDAQ market close on the day before trading begins. The underwriter presents its recommended price based on the order book, while the issuer’s board has the contractual right to reject the recommendation under the underwriting agreement’s terms. Data from the Hong Kong Stock Exchange’s 2024 IPO Review shows that for Main Board IPOs, 12.3% of issuers priced below the initial range, while for US IPOs of Chinese companies, the figure was 8.7% — suggesting that US underwriters are marginally more conservative in initial range setting.

The Mechanics of Price Range Setting and Final Price Determination

The pricing process in a US IPO follows a structured sequence from initial filing to final price determination, governed by SEC Regulations S-K and S-X, as well as FINRA Rule 5110 for underwriting compensation.

Initial Price Range and the SEC Review Period

The issuer files a registration statement on Form F-1 (for foreign private issuers) with a preliminary price range, typically a $2.00 band (e.g., $14.00-$16.00). The SEC review period averages 4-6 weeks for first-time filers, though the SEC’s Division of Corporation Finance has reduced median review times to 28 days in 2025, down from 35 days in 2023. During this period, the underwriter conducts an “education and pre-marketing” process with institutional investors, gathering non-binding indications of interest.

For Hong Kong issuers, a critical consideration is the interaction between the US IPO timeline and the HKEX Listing Committee’s hearing schedule if a dual-primary listing is contemplated. The SFC’s 2024 consultation paper on dual-listing disclosure requirements (SFC 2024, para 3.12) recommends that issuers align their US and Hong Kong prospectus (招股書) disclosures on risk factors related to PRC regulatory changes, particularly those under the State Council’s new regulations on overseas listings effective March 31, 2023.

Book-Building and the Order Book

The book-building process runs for 10-14 days, during which the underwriter collects orders from institutional investors. Each order specifies a price and quantity, creating a demand curve. The underwriter’s syndicate desk aggregates these orders into a “book” that shows cumulative demand at each price level. For a US IPO of a Hong Kong company, institutional demand typically accounts for 85-90% of the total offering, with retail participation limited to the 10-15% reserved for the retail tranche.

The underwriter uses the book to determine the “clearing price” — the price at which total demand equals the total shares offered. In practice, the clearing price is rarely chosen. Instead, the underwriter applies a 5-15% discount to the clearing price to create the first-day pop. For example, if the clearing price is $18.00, the underwriter might recommend $15.50-$16.50, depending on market conditions and the quality of the order book.

The Final Pricing Call and the Issuer’s Leverage

The final pricing call occurs at approximately 4:30 PM ET on the pricing day. The issuer’s board, represented by the CFO and legal counsel, reviews the underwriter’s recommendation. The issuer’s leverage at this stage depends on three factors: the quality of the order book (specifically, the ratio of “anchor” orders from long-only funds to “flipper” orders from hedge funds), the level of oversubscription (typically 2-5x for a well-received deal), and the issuer’s willingness to walk away from the offering.

Under the SEC’s Rule 415 (shelf offerings), an issuer can withdraw the registration statement and refile later, but this carries reputational cost. For Hong Kong issuers, walking away also triggers disclosure obligations under HKEX Listing Rule 13.09 on inside information, requiring an immediate announcement if the withdrawal is material to the company’s financial position.

Regulatory and Market Considerations Specific to Hong Kong Issuers

Hong Kong-based companies face distinct regulatory and market dynamics when pricing a US IPO, stemming from their corporate structure, PRC nexus, and the dual-regulatory environment.

The VIE Structure and Pricing Discount

Companies using a variable interest entity (VIE) structure — common among PRC-operating technology firms — face a structural pricing discount. The SEC’s 2021 guidance on VIE disclosure (SEC Release 33-10991) requires issuers to prominently disclose that shareholders own shares in a Cayman Islands holding company, not the PRC operating entity. This disclosure, combined with the risk of PRC regulatory action against VIE structures, leads to a 10-20% discount in IPO pricing relative to non-VIE peers.

Data from the 2024 IPOs of four Hong Kong-based VIE companies on NASDAQ shows an average first-day pop of 12.3%, compared to 15.1% for non-VIE Chinese companies. This narrower discount suggests that underwriters are pricing in the VIE risk more explicitly in the offer price rather than relying on the first-day pop to compensate investors.

The HKEX-SEC Dual Filing Obligation

Issuers pursuing a US IPO while maintaining a Hong Kong listing must navigate the dual filing requirements. The HKEX’s Listing Decision LD143-2023 clarified that a US IPO constitutes a “material acquisition or disposal” under Chapter 14 if the proceeds exceed 25% of the issuer’s market capitalisation. This triggers shareholder approval and disclosure requirements that can constrain the pricing flexibility — a board cannot accept a low price if it would violate the minimum price terms of the shareholder resolution.

The SFC’s 2025 enforcement priorities (SFC 2025 Annual Report, pp. 18-20) emphasise cross-border IPO pricing manipulation, specifically the practice of “underwriter-directed allocations” where the underwriter allocates shares to related parties at the offer price. Hong Kong issuers must ensure their pricing process complies with both SEC Regulation M (anti-manipulation) and the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (para 5.1-5.3 on fair allocation).

Currency and Hedging Considerations

For a Hong Kong issuer with HKD-denominated financial statements, the USD-denominated IPO proceeds create a currency exposure. The pricing decision must account for the HKD-USD peg (7.75-7.85), which has been maintained by the HKMA under the Linked Exchange Rate System since 1983. While the peg eliminates spot FX risk, the issuer faces translation risk on the IPO proceeds when converting to HKD for operational use in Hong Kong or the PRC.

The HKMA’s 2024 circular on IPO proceeds management (HKMA Circular 04/2024) recommends that issuers establish a USD-denominated trust account with an authorised institution in Hong Kong, with proceeds held until deployment. This structure allows the issuer to delay the currency conversion decision, but the pricing decision itself — specifically, the USD offer price — determines the total HKD-equivalent proceeds at the time of conversion.

Practical Strategies for Balancing Issuer and Underwriter Interests

The tension between issuer and underwriter interests can be managed through several structural and tactical mechanisms that align incentives without compromising either party’s objectives.

The Over-Allotment Option (Greenshoe) as a Pricing Tool

The greenshoe option, permitted under FINRA Rule 5110, allows the underwriter to sell up to 15% additional shares at the offer price. This mechanism directly aligns incentives: if the underwriter prices too high and the stock declines, it must buy back shares in the open market to cover its short position, incurring losses. If it prices too low, the greenshoe provides additional compensation through the spread on the extra shares.

For a Hong Kong issuer, the greenshoe should be structured to allow the underwriter to exercise the option in full only if the stock trades above the offer price for 30 consecutive days — a condition that can be written into the underwriting agreement. This creates a direct link between pricing discipline and aftermarket performance.

The Price Stabilisation Period

SEC Rule 104 of Regulation M permits the underwriter to stabilise the stock price for up to 30 days after the IPO by placing bids at or below the offer price. This stabilisation creates a floor that protects the offer price from immediate decline, but it also creates a moral hazard: the underwriter may price aggressively high, knowing it can use stabilisation to support the stock temporarily.

Hong Kong issuers should require the underwriter to disclose its stabilisation plan in the prospectus, including the maximum number of shares it intends to purchase and the duration of the stabilisation period. The SFC’s 2023 guidance on stabilisation practices (SFC Code of Conduct, para 7.2) recommends that issuers obtain independent legal advice on the stabilisation terms to ensure compliance with both SEC and SFC rules.

The Use of a Pricing Committee

Establishing a board-level pricing committee, composed of independent non-executive directors, provides a procedural safeguard against underpricing. The committee reviews the underwriter’s pricing recommendation against independent valuation reports and has the authority to reject the recommendation if it deviates materially from fair value.

For a Hong Kong issuer, the pricing committee should include at least one director with US capital markets experience, as required under HKEX Listing Rule 3.10A (independent directors with appropriate professional qualifications). The committee’s decision should be documented in board minutes, with specific reference to the valuation methodology used and the rationale for accepting or rejecting the underwriter’s price.

Actionable Takeaways

1. Price at a 10-15% discount to the clearing price, not the underwriter’s DCF valuation, to create a first-day pop that satisfies institutional investors without leaving excessive money on the table.
2. Negotiate a greenshoe option with a 30-day performance condition in the underwriting agreement to align underwriter compensation with aftermarket price stability.
3. Establish a board-level pricing committee with at least one independent director holding US capital markets expertise, as recommended by HKEX Listing Rule 3.10A and SFC guidance.
4. Disclose the VIE structure’s pricing impact explicitly in the prospectus, including a quantified range of the discount applied, to satisfy SEC Release 33-10991 requirements and reduce post-IPO litigation risk.
5. Require the underwriter to provide a written stabilisation plan in the prospectus, specifying maximum share purchases and duration, to ensure compliance with SEC Regulation M and the SFC Code of Conduct.